Miho Tanaka

Title: Miho Tanaka: Innovator in Cancer Therapeutics

Introduction

Miho Tanaka is a notable inventor based in Wako, Japan. He has made significant contributions to the field of cancer therapeutics through his innovative research and development of antibodies.

Latest Patents

Tanaka holds a patent for the Anti-Eva1 protein antibody. This invention aims to provide an antibody with high therapeutic and prophylactic effects against cancer. To achieve this, three types of mouse monoclonal antibodies were prepared, exhibiting high affinities for a human-derived Eva1 protein. Additionally, the constant regions of these antibodies were substituted with human-derived constant regions to create chimeric antibodies. These mouse and chimeric antibodies demonstrated high antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities. Furthermore, administering these antibodies to mice subjected to melanoma cell administration was found to suppress the metastasis of the cells to the lungs.

Career Highlights

Tanaka is affiliated with Hokkaido University, where he continues to advance his research in antibody development. His work has the potential to significantly impact cancer treatment and improve patient outcomes.

Collaborations

Tanaka collaborates with esteemed colleagues, including Mikako Shirouzu and Toru Kondo, who contribute to his research endeavors.

Conclusion

Miho Tanaka's innovative work in developing the Anti-Eva1 protein antibody showcases his commitment to advancing cancer therapeutics. His contributions are paving the way for new treatment options that could benefit many patients in the future.